Nonspecific Immunoeffector, Per Se (e.g., Adjuvant, Nonspecific Immunosti- Mulator, Nonspecific Immunopotentiator, Nonspecific Immunosuppressor, Non- Specific Immunomodulator, Etc.); Or Nonspecific Immunoeffector, Stabilizer, Emulsifier, Preservative, Carrier, Or Other Additive For A Composition Con- Taining An Immunoglobulin, An Antiserum, An Antibody, Or Fragment Thereof, An Antigen, An Epitope, Or Other Immunospecific Immunoeffector Patents (Class 424/278.1)
  • Patent number: 11547672
    Abstract: Non-liposome, non-micelle particles formed of a lipid, an additional adjuvant such as a TLR4 agonist, a sterol, and a saponin are provided. The particles are porous, cage-like nanoparticles, also referred to as nanocages, and are typically between about 30 nm and about 60 nm. In some embodiments, the nanocages include or are administered in combination with an antigen. The particles can increase immune responses and are particularly useful as adjuvants in vaccine applications and related methods of treatment. Preferred lipids, additional adjuvants including TLR4 agonists, sterols, and saponins, methods of making the nanocages, and method of using them are also provided.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: January 10, 2023
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, LA JOLLA INSTITUTE FOR IMMUNOLOGY
    Inventors: Darrell J. Irvine, Murillo Silva, Shane Crotty, Yu Kato
  • Patent number: 11479823
    Abstract: Provided herein is technology for lung neoplasia screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of lung cancer.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: October 25, 2022
    Assignee: Exact Sciences Corporation
    Inventors: Hatim Allawi, Graham P. Lidgard, Chateen Krueger, Michael W. Kaiser, Tamara J. Sander
  • Patent number: 11446227
    Abstract: The present invention provides a method for preparing an high internal phase of pumpkin seed protein nanoparticles, including dissolving pumpkin seed protein powder in water and adjusting pH to approximately 8 to 11 to obtain a pumpkin seed protein solution; adding the pumpkin seed protein solution through a peristaltic pump into an ethanol solution with stirring for 4 hours to obtain a first solution; performing a centrifugation to the first solution and collecting precipitates; diluting the precipitates with water and performing a freeze-drying to obtain the pumpkin seed protein nanoparticles. The present invention first uses an anti-solvent method to prepare pumpkin seed protein nanoparticles, which have excellent emulsifying properties and can stabilize the high internal phase emulsion. In addition, the resulting pumpkin seed protein nanoparticles can stabilize the high internal phase emulsion independently without compounding with other substances.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: September 20, 2022
    Assignee: Jiangnan University
    Inventors: Jing Wang, Yongqiang Shen, Cheng Yang, Guangqun Cao
  • Patent number: 11447550
    Abstract: This disclosure relates to synthetic ligands for detecting PD-L1 in a sample or subject. The ligand can be labeled with a variety of detectable labels allowing of visualization and quantification. The ligand provides an alternative PD-L1 binding molecule with advantages over current antibody technologies for detecting PD-L1.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: September 20, 2022
    Assignee: The Curators of the University of Missouri
    Inventors: Raghuraman Kannan, Charles Caldwell, Jr., Vitukudi Narayanaiyengar Balaji, Govardhan Aadharsh Balaji
  • Patent number: 11406693
    Abstract: A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: August 9, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Andrea Mahr, Jens Fritsche, Phillip Mueller, Anita Wiebe, Sarah Kutscher
  • Patent number: 11358988
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: June 14, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
  • Patent number: 11344631
    Abstract: The present invention refers to nucleotide sequences used for driving the expression of a therapeutic gene, preferably FVIII and/or its variants specifically in endothelial cells and/or hematopoietic, preferably myeloid cells. The sequences are useful for gene and/or cell therapy, preferably for treating hemophilia, more preferably type A hemophilia.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: May 31, 2022
    Assignee: Universita' del Piemonte Orientale
    Inventors: Antonia Follenzi, Diego Zanolini, Rosella Fama', Simone Merlin
  • Patent number: 11319343
    Abstract: The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: May 3, 2022
    Assignees: ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY, UNIVERSITY OF SOUTH AUSTRALIA, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEEN ELIZABETH NEAR DUBLIN, MONASH UNIVERSITY
    Inventors: Stavros Selemidis, Doug A. Brooks, John O'Leary
  • Patent number: 11318200
    Abstract: The invention provides a substantially antigen-free composition for induction of innate immune response in a bird or a mammal, the composition comprising a saponin, a sterol, a quaternary amine, and a polyacrylic polymer to the mammal or bird. Methods of using the composition are also provided.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: May 3, 2022
    Assignee: Zoetis Services LLC
    Inventors: Paul Joseph Dominowski, Duncan Mwangi, Joseph M. Bricker, Dennis L. Foss, Sharath K. Rai, Suman Mahan
  • Patent number: 11278612
    Abstract: Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: March 22, 2022
    Assignee: Novavax, Inc.
    Inventors: Sarathi Boddapati, Anushree Herwadkar, Jason Wong, Yen-Huei Lin, Gale Smith, Jing-Hui Tian
  • Patent number: 11278604
    Abstract: A composition comprising mesoporous silica rods comprising an immune cell recruitment compound and an immune cell activation compound, and optionally comprising an antigen such as a tumor lysate. The composition is used to elicit an immune response to a vaccine antigen.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: March 22, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Jaeyun Kim, Weiwei Aileen Li, David J. Mooney
  • Patent number: 11266602
    Abstract: Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: March 8, 2022
    Assignee: INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Christopher B. Fox, Susan S. Lin, Darrick Carter, Neal Van Hoeven, Mayuresh M. Abhyankar, William A. Petri
  • Patent number: 11149066
    Abstract: Provided is a compound that can promote angiogenesis by inhibiting the function of TSP1, and is useful for the treatment or prophylaxis of diseases such as critical limb ischemia.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: October 19, 2021
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, PEPTIDREAM INC.
    Inventors: Takahiro Yamaguchi, Yutaka Mori, Hironao Saito, Hideki Kubota, Akihiro Furukawa, Eri Otsuka, Yutaka Ishigai, Hiroshi Ijiri, Patrick Reid
  • Patent number: 11103605
    Abstract: The invention relates to the synthesis and use of 18F-labeled millamolecules for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: August 31, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: David J. Donnelly, Kenneth M. Boy, Yunhui Zhang, Joonyoung Kim, Adrienne Pena
  • Patent number: 11077045
    Abstract: Methods of using Shilajit or its individual components, or a combination of two or more of these components, to improve skin microperfusion, to upregulate ECM related genes in the skin, to increase endothelial cell migration and growth of blood vessels, and thus to improve skin health are presented herein.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: August 3, 2021
    Assignee: Natreon, Inc.
    Inventors: Chandan K. Sen, Sanyasi R. Kalidindi
  • Patent number: 11073509
    Abstract: Provided herein are methods for determining the functional status of a cellular pathway in a diseased cell sample obtained from an individual subject. These methods involve contacting a diseased cell sample obtained from the subject with a perturbing agent (e.g., an activating agent) known to perturb a specific cellular pathway when the pathway is functioning normally. A change in one or more physiological response parameters in the presence of the perturbing agent indicates that the cellular pathway targeted by the perturbing agent is functional in the individual subject. Methods of selecting a targeted therapeutic agent for an individual subject are also provided.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: July 27, 2021
    Assignee: Celcuity Inc.
    Inventors: Lance Gavin Laing, Brian Francis Sullivan
  • Patent number: 11071753
    Abstract: Engineered dendritic cell vaccines, and methods of forming and applying same, that may be used as effective immunotherapies for cancers.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: July 27, 2021
    Assignee: University of South Carolina
    Inventor: Daping Fan
  • Patent number: 11053297
    Abstract: Disclosed herein are methods of increasing numbers of monocytes to a tumor or cancer metastasis site in a subject. Non-limiting embodiments include administering or using a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+ GR1? (Ly6C?)) monocytes; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist. Also disclosed herein are methods of increasing, stimulating, activating or promoting monocyte migration to or mobilization against a tumor or cancer metastasis in a subject. Non-limiting embodiments include administering a Nur77 polypeptide or subsequence thereof; a Nur77 agonist; a CX3CR1 agonist; CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes; or CD14+ CD16+ monocytes and/or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes contacted with a Nur77 agonist or contacted with a CX3CR1 agonist.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: July 6, 2021
    Assignee: La Jolla Institute for Allergy and Immunology
    Inventors: Catherine C. Hedrick, Richard Hanna
  • Patent number: 11040107
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: June 22, 2021
    Assignee: Apellis Pharmaceuticals, Inc.
    Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
  • Patent number: 10993980
    Abstract: Present disclosure provides a pharmaceutical composition or a preparation composition containing fermented papaya preparation as an active ingredient for treating a patient with electrohypersensitivity or relieving a symptom thought to be a symptom of the electrohypersensitivity, and methods of use thereof.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: May 4, 2021
    Assignee: Osato International Inc.
    Inventors: Yukiyasu Hayashi, Dominique Belpomme
  • Patent number: 10925880
    Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of PI3K kinase, and component B being venetoclax or palbociclib.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: February 23, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventor: Martin Lange
  • Patent number: 10925944
    Abstract: The invention pertains to a cell population for use in treating cancer in a patient, comprising CD1c(BDCA-1)+/CD19? dendritic cells, wherein CD1c(BDCA-1)+/CD19? dendritic cells are depleted for CD1c(BDCA-1)+/CD19?/CD14+ cells.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: February 23, 2021
    Assignee: MILTENYI BIOTEC B.V. & CO. KG
    Inventors: Jolanda De Vries, Carl Figdor, Ghaith Bakdash
  • Patent number: 10799592
    Abstract: The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: October 13, 2020
    Assignee: UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION
    Inventors: Warren O. Haggard, Scott P. Noel, Joel D. Bumgardner
  • Patent number: 10782300
    Abstract: The present invention discloses a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or a patient or determining the continuation of GPC3-targeting drug therapy for a patient, including monitoring a concentration of free GPC3 in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the concentration of free GPC3 is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. The present invention also discloses a GPC3-targeting drug or a preparation which is to be further administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: September 22, 2020
    Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, F. Hoffmann-La Roche AG
    Inventors: Toshihiko Ohtomo, Ya-Chi Chen, Jun Amano, Mikiko Nakamura
  • Patent number: 10718755
    Abstract: A method for screening a pharmaceutical compound for prevention, alleviation and/or treatment of steatohepatitis, the method including employing N-terminal dimerization of an apoptosis signal-regulated kinase 1 as a target.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: July 21, 2020
    Assignee: WUHAN UNIVERSITY
    Inventor: Hongliang Li
  • Patent number: 10639367
    Abstract: The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides compositions (e.g., vaccines) and methods of using the same for the induction of immune responses (e.g., innate and adaptive immune responses (e.g., for generation of host immunity against cancer (e.g., a tumor) or against any type of antigen (e.g. bacterial, viral, parasite-derived)). Compositions and methods of the present invention find use in, among other things, clinical (e.g. prophylactic, therapeutic and preventive medicine (e.g., vaccination)) and research applications. It particularly relates to the area of active specific immunotherapy of cancer (“cancer vaccines”), and provides procedures for the preparation of therapeutic vaccines that can eliminate cancer cells.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: May 5, 2020
    Assignee: CYTUVAX
    Inventor: Frank Walter Falkenberg
  • Patent number: 10583178
    Abstract: The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a ?-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: March 10, 2020
    Assignee: NUTRAMAX LABORATORIES, INC.
    Inventors: Brian Cornblatt, Grace Cornblatt, Anton Bzhelyansky, Robert Henderson
  • Patent number: 10561686
    Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: February 18, 2020
    Assignee: Innovative Cellular Therapeutics Co., Ltd.
    Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Zhao Wu
  • Patent number: 10543168
    Abstract: A formulation for generating an adhesion barrier that includes a plurality of particles or a dry powder that is made of a polymer combination of at least one biodegradable polymer and at least one water soluble polymer is disclosed. Methods of making and delivering the formulation are further disclosed. The formulation of particles is deposited on a surface of internal body tissue and the deposited formulation absorbs moisture from the tissue and forms a film over the surface. The film acts as an adhesion barrier by reducing or preventing adhesion of the surface to other body tissue.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: January 28, 2020
    Assignee: Ara Medical, LLC
    Inventors: Donald J. Eaton, Bin Huang, Michael A. Savitt
  • Patent number: 10544088
    Abstract: The present disclosure provides pharmaceutically acceptable stable salt forms of 15-lipoxygenase products, such as 15-HETrE lysine salt, compositions comprising same and methods of making and using same.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: January 28, 2020
    Assignee: DS Biopharma Limited
    Inventors: Mehar Manku, David Coughlan, Bill Downes
  • Patent number: 10543248
    Abstract: The present invention relates to a pharmaceutical composition, which comprises a Stemonae Radix extract, for preventing or treating the occurrence of inflammatory bowel diseases due to cigarette smoke, a method for preventing or treating the occurrence of inflammatory bowel diseases using the composition, a method for suppressing the expression of inflammatory cytokines using the composition, and to a food composition, which comprises the Stemonae Radix extract, for preventing or treating the occurrence of inflammatory bowel diseases due to cigarette smoke.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: January 28, 2020
    Assignee: University-Industry Cooperation Group of Kyung Hee University
    Inventors: Jin Ju Kim, Eun Jung Ko, Eui Jeoung Lee
  • Patent number: 10537625
    Abstract: Engineered dendritic cell vaccines, and methods of forming and applying same, that may be used as effective immunotherapies for cancers.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: January 21, 2020
    Assignee: University of South Carolina
    Inventor: Daping Fan
  • Patent number: 10508069
    Abstract: The invention provides a method for preparing a carboxylic acid, which method includes the steps of providing magnesium carboxylate, wherein the carboxylic acid corresponding with the carboxylate has a solubility in water at 20° C. of 80 g/100 g water or less; acidifying the magnesium carboxylate with HCl, thereby obtaining a solution comprising carboxylic acid and magnesium chloride (MgCl2); optionally a concentration step, wherein the solution comprising carboxylic acid and MgCl2 is concentrated; precipitating the carboxylic acid from the solution comprising the carboxylic acid and MgCl2, thereby obtaining a carboxylic acid precipitate and a MgCl2 solution.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: December 17, 2019
    Assignee: PURAC BIOCHEM B.V.
    Inventors: André Banier De Haan, Jan Van Breugel, Paulus Loduvicus Johannes Van Der Weide, Peter Paul Jansen, José Maria Vidal Lancis, Agustin Cerdà Baró
  • Patent number: 10456459
    Abstract: The invention provides a liposomal adjuvant composition comprising an external membrane and an internal compartment, the external membrane comprising: a quaternary ammonium compound; a sterol; a phospholipid; and a glycolipid. Vaccine compositions comprising the liposomal adjuvant of the instant invention are also provided.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: October 29, 2019
    Assignee: Zoetis Services LLC
    Inventors: Paul Joseph Dominowski, Duncan Mwangi, Sharath K. Rai, Dennis L. Foss, Traci K. Godbee, Laurel Mary Sly, Suman Mahan, Shaunak Vora
  • Patent number: 10456427
    Abstract: Lobster hemolymph and compositions derived therefrom for the prevention or treatment of viral diseases or cancer by systemic administration.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: October 29, 2019
    Assignee: Lobster Unlimited LLC
    Inventor: Robert C. Bayer
  • Patent number: 10434142
    Abstract: Compositions and methods are contemplated for treatment of a wound, and especially a sterile or TLR/NOD ligand-poor wound in which contemporaneous administration of a Ca2+-flux agonist (CFA) and a pattern recognition receptor (PRR) ligand improves wound healing.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: October 8, 2019
    Assignee: Chan Soon-Shiong Nanthealth Foundation
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Oleksandr Buzko, Anne-Laure Le Ny, Patrick Soon-Shiong
  • Patent number: 10398767
    Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: September 3, 2019
    Inventors: Simon Urwyler, Markus Haake, Michael Rudolf
  • Patent number: 10365272
    Abstract: The present disclosure relates to the field of immunoassays for Gram negative bacteria, in particular N. meningitidis. The disclosure provides a simple and affordable immunoassay to quantitate polysaccharides in meningococcal vaccines for the evaluation of antigen content and lot-to-lot manufacturing consistency. The inventors have found a Sandwich ELISA that can be applicable for the quantitation and identification of N. meningitidis serogroup X polysaccharide in a multivalent meningococcal polysaccharide-protein conjugate vaccine as well as in a multivalent meningococcal plain polysaccharide vaccine. Said assay employs a polyclonal antibody as capture antibody and a novel monoclonal antibody against serogroup X polysaccharide as detection antibody. Further the assay is rapid, robust and reproducible.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: July 30, 2019
    Assignee: SERUM INSTITUTE OF INDIA PRIVATE LIMITED
    Inventors: Kale Sameer Manohar, Sharma Pankaj Keshav, Gairola Sunil Jagdishprasad
  • Patent number: 10358463
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: July 23, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Ling Li, Michael S. Bowsher, Eric P. Gillis, Eric Mull, Qian Zhao, Li-Qiang Sun, David R. Langley, Paul Michael Scola
  • Patent number: 10342842
    Abstract: A method of producing a substance with antimicrobial, antiviral, and immunostimulatory activities, particularly towards dendritic cells is proposed, provides for using the chopped potato sprouts as plant raw materials are extracted with water, then the aqueous extract is centrifuged, a salt agent is added, and the obtained saline solution is then concentrated using ultrafiltration through a 300-kD filter, then the solution is frozen for 24 hours, thawed, and filtered, and the pellet thus obtained is removed, and the raw peptidoglycan is precipitated from the solution by using an acidic salt agent and is further re-solubilized with alkali, then the alkaline solution is dialyzed against distilled water on a 12 kD filter, and the peptidoglycan having a molecular weight of 500 kD to 17000 kD is purified from the resulting solution using gel permeation chromatography.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: July 9, 2019
    Assignee: 9541659 Canada Inc.
    Inventors: Ravshan I. Ataullakhanov, Aleksey V. Pichugin, Tatyana M. Melnikova, Rakhim M. Khaitov
  • Patent number: 10328115
    Abstract: The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: June 25, 2019
    Assignee: Ra Pharmaceuticals, Inc.
    Inventors: Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter
  • Patent number: 10329408
    Abstract: A thermoplastic resin composition and a molded article produced using the same. The thermoplastic resin composition includes: a polyester resin comprising a repeat unit represented by Formula 1; a white pigment; and glass fillers comprising glass fibers having a circular cross-section and an average sectional diameter of about 6 ?m to about 8 ?m and flat glass fibers having a sectional aspect ratio of about 1.5 to about 8, wherein a weight ratio of the glass fibers to the flat glass fibers (circular shape:flat shape) ranges from about 1:0.1 to about 1:6, wherein Ar is a C6 to C18 arylene group; R1 and R3 are the same or different and are each independently a C1 to C10 linear alkylene group; and R2 is a C5 to C12 cyclic alkylene group. The thermoplastic resin composition and the molded article produced using the same can exhibit excellent reflectance, impact resistance, stiffness, and balance therebetween.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: June 25, 2019
    Assignee: Lotte Advanced Materials Co., Ltd.
    Inventors: Young Ho Park, Chan Moo Park, Tae Gon Kang, Sang Hyun Hong
  • Patent number: 10300106
    Abstract: An autophagy-inducing compound comprises an autophagy-inducing peptide comprising Beclin 1 peptides immediately N- and C-terminally flanked by moieties R1 and R2, respectively, wherein up to six of said peptide residues may be substituted, R1 and R2 do not naturally flank the Beclin 1 residues, and F270 and F274 are optionally substituted and optionally linked. The compounds may be used to induce autophagy.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: May 28, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Beth C. Levine, Sanae Shoji-Kawata, Nick V. Grishin, Lisa N. Kinch, Olivier Lichtarge, Angela D. Wilkins
  • Patent number: 10293019
    Abstract: An object of the present invention is to provide a novel treatment method with fewer side effects for elderly cancer patients and terminal cancer patients. A pharmaceutical composition for treating or putting an elderly or a terminal cancer patient into remission, comprising, as an active ingredient, (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: May 21, 2019
    Assignee: DELTA-FLY PHARMA, INC.
    Inventor: Hiromi Wada
  • Patent number: 10245313
    Abstract: The present invention relates to the field of applied immunotechnology and medicine. More specifically, it relates to DNA motif vaccine design, glyco-DNA motif vaccine design, and immunogen design for producing antibodies against an epitope of arbitrary sequences or polysaccharide epitope, particularly those epitopes against which it is otherwise very difficult to induce antibodies, such as those of HIV-1. The present invention also relates to immunogen design to induce robust cellular and humoral immunity.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: April 2, 2019
    Assignees: VERSITECH LIMITED, NANJING UNIVERSITY
    Inventors: Zhiwei Chen, Xilin Wu, Zhiwei Wu
  • Patent number: 10220097
    Abstract: A method for treating a patient suffering from a condition with an active compound comprising the steps of (a) treating the patient intranasally with an effective amount of MMP-9 or a functionally equivalent fragment, wherein the tight junctions of the patient's nasal epithelial cells are modulated or wherein the basal lamina of the patient is partially digested and type IV collagen of the patient is degraded or wherein access to the patient's perineural, perivascular, or lymphatic compartment spaces is facilitated and (b) treating the patient intranasally with an active compound is disclosed.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: March 5, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Robert Gary Thorne, Jeffrey James Lochhead
  • Patent number: 10206998
    Abstract: Provided herein are methods for making targeted therapeutics. In several embodiments, the therapeutics are directed against soluble agents such as toxins, venoms, and/or other factors that alter physiological biopathways as well as methods of using such therapeutics to treat patients or patient populations to reduce, eliminate, or inactivate, detrimental soluble agents that such patients or patient populations have been exposed to. In several embodiments, the therapeutics are directed to patient-specific disease markers. In several embodiments, the methods comprise screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: February 19, 2019
    Assignee: ProteoNova, Inc.
    Inventors: Richard B Williams, Robert Guerrero
  • Patent number: 10195270
    Abstract: This peptide/?-1,3-glucan complex includes ?-1,3-glucan and a peptide/polynucleotide conjugate in which an antigenic peptide is bonded covalently to a polynucleotide or a derivative thereof. The polynucleotide or derivative thereof of the peptide/polynucleotide conjugate bonds via a hydrogen bond with ?-1,3-glucan, forming a complex having a triple helix structure including a single molecular chain of the polynucleotide or derivative thereof and two molecular chains of the ?-1,3-glucan. Alternatively, the side chain of the ?-1,3-glucan and the antigenic peptide are bonded covalently formed by either a cycloaddition reaction between an alkyne and an azide derivative, or a reaction between a maleimide group or a vinyl sulfone group and a thiol group.
    Type: Grant
    Filed: December 25, 2014
    Date of Patent: February 5, 2019
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Kazuo Sakurai, Shin-ichi Mochizuki, Hiromi Morishita
  • Patent number: 10143746
    Abstract: The present disclosure provides novel macrocyclic compounds which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: December 4, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Martin Patrick Allen, Eric P. Gillis, David R. Langley, Michael Matthew Miller, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Katharine A. Grant-Young, Nicholas A. Meanwell, Paul Michael Scola
  • Patent number: 10111899
    Abstract: The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: October 30, 2018
    Assignee: Dynavax Technologies Corporation
    Inventors: Cristiana Guiducci, Robert L. Coffman